Apricus Biosciences Provides Third Quarter 2013 Corporate Update

SAN DIEGO, Nov. 13, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus" or the "Company") (Nasdaq:APRI) (www.apricusbio.com), today provided a third quarter corporate update, including clinical, commercial and regulatory strategies for its topical on-demand product Vitaros® for erectile dysfunction ("ED") and its product candidate Femprox® for female sexual interest/arousal disorder ("FSIAD").

Help employers find you! Check out all the jobs and post your resume.